{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:32:48Z","timestamp":1750836768852},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>\n            <jats:bold>Aims:<\/jats:bold>\n            Evaluate the impact of quetiapine extended release (XR) versus quetiapine immediate release (IR) on hospitalization length in acute bipolar mania using Truven Health Analytics MarketScan\n            <jats:sup>\u00ae<\/jats:sup>\n            Hospital Drug Database.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            Generalized linear model analyses were used, adjusting for patient and hospital characteristics.\n            <jats:bold>Results:<\/jats:bold>\n            Using data from 3088 discharges, quetiapine XR reduced hospitalization length by 6.7% versus quetiapine IR (p = 0.11; no statistically significant differences between groups), corresponding to 0.6 fewer days in hospital. Excluding the outlier, quetiapine XR significantly reduced hospitalization length by 9.6% versus quetiapine IR (p = 0.02), corresponding to 0.9 days.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Inpatient use of quetiapine XR in acute bipolar mania may be associated with reduced hospitalization length (7\u201310%), possibly owing to the faster titration schedule versus quetiapine IR.\n          <\/jats:p>","DOI":"10.2217\/cer.14.48","type":"journal-article","created":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T09:39:55Z","timestamp":1409305195000},"page":"51-59","source":"Crossref","is-referenced-by-count":3,"title":["Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania"],"prefix":"10.57264","volume":"4","author":[{"given":"Machaon","family":"Bonafede","sequence":"first","affiliation":[{"name":"Truven Health Analytics, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C","family":"Locklear","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wahlqvist","sequence":"additional","affiliation":[{"name":"AstraZeneca R&amp;D, M\u00f6lndal, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liberty","family":"Fajutrao","sequence":"additional","affiliation":[{"name":"AstraZeneca, S\u00f6dert\u00e4lje, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Szamosi","sequence":"additional","affiliation":[{"name":"AstraZeneca, S\u00f6dert\u00e4lje, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"Pan","sequence":"additional","affiliation":[{"name":"Truven Health Analytics, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[{"name":"AstraZeneca, S\u00f6dert\u00e4lje, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/07853890802409489","article-title":"Treatment of bipolar disorder: new perspectives","volume":"41","author":"Alda M","year":"2009","unstructured":"Alda M , Hajek T , Calkin C , O'Donovan C . Treatment of bipolar disorder: new perspectives . Ann. Med. 41 ( 3 ), 186 \u2013 196 ( 2009 ).","journal-title":"Ann. Med."},{"issue":"7","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/ps.2006.57.7.927","article-title":"Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial","volume":"57","author":"Bauer MS","year":"2006","unstructured":"Bauer MS , McBride L , Williford WO Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial . Psychiatr. Serv. 57 ( 7 ), 927 \u2013 936 ( 2006 ).","journal-title":"Psychiatr. Serv."},{"issue":"5","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas KR","year":"2007","unstructured":"Merikangas KR , Akiskal HS , Angst J Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication . Arch. Gen. Psychiatry 64 ( 5 ), 543 \u2013 552 ( 2007 ).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/PCC.v09n0405","article-title":"Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database","volume":"9","author":"Ohsfeldt RL","year":"2007","unstructured":"Ohsfeldt RL , Lage MJ , Rajagopalan K . Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database . Prim. Care Companion J. Clin. Psychiatry 9 ( 4 ), 280 \u2013 286 ( 2007 ).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"issue":"1","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ps.2007.58.1.85","article-title":"Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders","volume":"58","author":"Baldessarini RJ","year":"2007","unstructured":"Baldessarini RJ , Leahy L , Arcona S , Gause D , Zhang W , Hennen J . Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders . Psychiatr. Serv. 58 ( 1 ), 85 \u2013 91 ( 2007 ).","journal-title":"Psychiatr. Serv."},{"issue":"6","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1034\/j.1399-5618.2002.01148.x","article-title":"Health care utilization and costs among privately insured patients with bipolar I disorder","volume":"4","author":"Bryant-Comstock L","year":"2002","unstructured":"Bryant-Comstock L , Stender M , Devercelli G . Health care utilization and costs among privately insured patients with bipolar I disorder . Bipolar. Disord. 4 ( 6 ), 398 \u2013 405 ( 2002 ).","journal-title":"Bipolar. Disord."},{"issue":"9","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/appi.ps.51.9.1184","article-title":"Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder","volume":"51","author":"Dalkilic A","year":"2000","unstructured":"Dalkilic A , Diaz E , Baker CB , Pearsall HR , Woods SW . Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder . Psychiatr. Serv. 51 ( 9 ), 1184 \u2013 1186 ( 2000 ).","journal-title":"Psychiatr. Serv."},{"key":"e_1_3_4_10_2","unstructured":"National Center for Health Statistics\n                                            . \n                                            National health expenditures for mental health services average annual percent change and percent distribution by type of expenditure: United States selected years 1986\u20132005\n                                            . \n                                            www.cdc.gov\/nchs\/data\/hus\/2010\/128.pdf\n                                            \u00a0"},{"issue":"1","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jad.2010.08.030","article-title":"An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009","volume":"129","author":"Dilsaver SC","year":"2011","unstructured":"Dilsaver SC . An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009 . J. Affect. Disord. 129 ( 1\u20133 ), 79 \u2013 83 ( 2011 ).","journal-title":"J. Affect. Disord."},{"key":"e_1_3_4_12_2","unstructured":"AstraZeneca UK Limited\n                                            . \n                                            Seroquel summary of product characteristics (UK)\n                                            . \n                                            www.medicines.org.uk\/emc\/medicine\/2295"},{"key":"e_1_3_4_13_2","unstructured":"AstraZeneca Pharmaceuticals LP\n                                            . \n                                            Seroquel XR\u00ae (quetiapine fumarate) prescribing information\n                                            . \n                                            www1.astrazeneca-us.com\/pi\/seroquel.pdf"},{"key":"e_1_3_4_14_2","unstructured":"AstraZeneca Pharmaceuticals LP\n                                            . \n                                            Seroquel XR\u00ae (quetiapine fumarate) extended release tablets prescribing information\n                                            . \n                                            www1.astrazeneca-us.com\/pi\/seroquelxr.pdf"},{"key":"e_1_3_4_15_2","unstructured":"AstraZeneca UK Limited\n                                            . \n                                            Seroquel XL\u00ae summary of product characteristics (UK)\n                                            . \n                                            www.medicines.org.uk\/EMC\/medicine\/21175\/SPC"},{"issue":"1","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v66n0116","article-title":"A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder","volume":"66","author":"Bowden CL","year":"2005","unstructured":"Bowden CL , Grunze H , Mullen J A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder . J. Clin. Psychiatry 66 ( 1 ), 111 \u2013 121 ( 2005 ).","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.euroneuro.2005.02.006","article-title":"Quetiapine or haloperidol as monotherapy for bipolar mania \u2013 a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial","volume":"15","author":"McIntyre RS","year":"2005","unstructured":"McIntyre RS , Brecher M , Paulsson B , Huizar K , Mullen J . Quetiapine or haloperidol as monotherapy for bipolar mania \u2013 a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial . Eur. Neuropsychopharmacol. 15 ( 5 ), 573 \u2013 585 ( 2005 ).","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","article-title":"Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies","volume":"21","author":"Vieta E","year":"2005","unstructured":"Vieta E , Mullen J , Brecher M , Paulsson B , Jones M . Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies . Curr. Med. Res. Opin 21 ( 6 ), 923 \u2013 934 ( 2005 ).","journal-title":"Curr. Med. Res. Opin"},{"issue":"11","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.clinthera.2011.10.002","article-title":"Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial","volume":"33","author":"Cutler AJ","year":"2011","unstructured":"Cutler AJ , Datto C , Nordenhem A , Minkwitz M , Acevedo L , Darko D . Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial . Clin. Ther. 33 ( 11 ), 1643 \u2013 1658 ( 2011 ).","journal-title":"Clin. Ther."},{"issue":"2","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","article-title":"Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release","volume":"33","author":"Figueroa C","year":"2009","unstructured":"Figueroa C , Brecher M , Hamer-Maansson JE , Winter H . Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release . Prog. Neuropsychopharmacol. Biol. Psychiatry 33 ( 2 ), 199 \u2013 204 ( 2009 ).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.eurpsy.2008.01.918","article-title":"Does prescribing practice of clozapine affect length of stay in psychiatric in-patient units?","volume":"23","author":"Agrawal V","year":"2008","unstructured":"Agrawal V , Agell I . Does prescribing practice of clozapine affect length of stay in psychiatric in-patient units? Eur. Psychiatry 23 ( Suppl. 2 ), S154 \u2013 S155 ( 2008 ).","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison LP\u00a0","year":"2007","unstructured":"Garrison LP\u00a0 Jr , Neumann PJ , Erickson P , Marshall D , Mullins CD . Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report . Value Health 10 ( 5 ), 326 \u2013 335 ( 2007 ).","journal-title":"Value Health"},{"key":"e_1_3_4_23_2","unstructured":"Hughes\n                                                    J\n                                            . \n                                            Development of the 3M\u2122 All Patient Refined Diagnosis Related Groups (APR DRGs)\n                                            . \n                                            www.ahrq.gov\/professionals\/quality-patient-safety\/quality-resources\/tools\/mortality\/Hughes.pdf"},{"issue":"3","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1399-5618.2007.00394.x","article-title":"Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications","volume":"9","author":"Gianfrancesco F","year":"2007","unstructured":"Gianfrancesco F , Rajagopalan K , Goldberg JF , Wang RH . Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications . Bipolar Disord. 9 ( 3 ), 252 \u2013 261 ( 2007 ).","journal-title":"Bipolar Disord."},{"issue":"1","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2146\/ajhp060635","article-title":"Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia","volume":"65","author":"Strutton DR","year":"2008","unstructured":"Strutton DR , Gutierrez B , Blanchette CM . Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia . Am. J. Health Syst. Pharm. 65 ( 1 ), 42 \u2013 48 ( 2008 ).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/NDT.S14369","article-title":"Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders","volume":"8","author":"El-Khalili N","year":"2012","unstructured":"El-Khalili N . Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders . Neuropsychiatr. Dis. Treat 8 , 523 \u2013 536 ( 2012 ).","journal-title":"Neuropsychiatr. Dis. Treat"},{"issue":"9","key":"e_1_3_4_27_2","first-page":"S22","article-title":"Statistical issues with the analysis of nonrandomized studies in comparative effectiveness research","volume":"17","author":"Alemayehu D","year":"2011","unstructured":"Alemayehu D , Alvir JM , Jones B , Willke RJ . Statistical issues with the analysis of nonrandomized studies in comparative effectiveness research . J. Manag. Care Pharm. 17 ( 9 Suppl. A ), S22 \u2013 S26 ( 2011 ).","journal-title":"J. Manag. Care Pharm."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.14.48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:21Z","timestamp":1679231721000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.14.48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.2217\/cer.14.48"],"URL":"https:\/\/doi.org\/10.2217\/cer.14.48","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}